A real-world study to assess initial experience with bevacizumab-awwb in a post-approval community oncology setting
Latest Information Update: 25 Feb 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Pharmacodynamics; Therapeutic Use
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium
- 24 Jul 2020 New trial record
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer